Related Experiment Video
Updated: Aug 25, 2025
08:52
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
Published on: June 13, 2018
8.9K
ICSBP-induced PD-L1 enhances osteosarcoma cell growth
Jee Young Sung1, June Hyuk Kim2, Hyun Guy Kang2
1Metastasis Branch, Division of Cancer Biology, National Cancer Center, Goyang, South Korea.
Frontiers in Oncology
|October 17, 2022
Summary
Interferon consensus sequence binding protein (ICSBP) regulates programmed death-ligand 1 (PD-L1) in osteosarcoma. Targeting PD-L1 with doxorubicin may treat osteosarcoma expressing ICSBP.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Interferon (IFN) consensus sequence binding protein (ICSBP) is an IFN-γ-induced transcription factor.
- ICSBP expression promotes osteosarcoma progression via transforming growth factor-β signaling.
- Programmed death-ligand 1 (PD-L1) contributes to immune escape and tumor progression in cancer.
Purpose of the Study:
- To investigate the association between ICSBP and PD-L1 expression in osteosarcoma progression.
- To explore the functional role of PD-L1 in osteosarcoma cells.
- To evaluate the therapeutic potential of targeting PD-L1 in osteosarcoma.
Main Methods:
- Utilized three osteosarcoma cell lines (Saos2, U2OS, 143B).
- Assessed gene and protein expression via qRT-PCR and immunoblotting.
- Evaluated PD-L1 effects on cell growth, cell cycle, apoptosis, and tumor xenografts in vivo.
Main Results:
- ICSBP overexpression upregulated PD-L1, while ICSBP knockdown decreased it.
- PD-L1 knockdown attenuated cell growth, reduced colony formation, increased apoptosis, and induced G2/M arrest.
- PD-L1 knockdown decreased tumor xenograft growth and enhanced doxorubicin sensitivity.
Conclusions:
- ICSBP regulates PD-L1 expression in osteosarcoma cells.
- PD-L1 knockdown combined with doxorubicin treatment is a potential therapeutic strategy for ICSBP-expressing osteosarcoma.
